Get the Stockscreener App
2.31
0.87%
0.02
After Hours:
2.25
-0.06
-2.60%
Polaryx Therapeutics Inc stock is traded at $2.31, with a volume of 90,327.
It is up +0.87% in the last 24 hours and down -13.48% over the past month.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
See More
Previous Close:
$2.29
Open:
$2.26
24h Volume:
90,327
Relative Volume:
0.19
Market Cap:
$115.14M
Revenue:
-
Net Income/Loss:
$-6.48M
P/E Ratio:
-16.86
EPS:
-0.137
Net Cash Flow:
$-5.30M
1W Performance:
+2.21%
1M Performance:
-13.48%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.26
$2.42
1-Week Range:
$2.23
$2.52
52-Week Range:
$2.01
$33.90
Polaryx Therapeutics Inc Stock (PLYX) Company Profile
Name
Polaryx Therapeutics Inc
Sector
Industry
Phone
201-940-7236
Address
140 EAST RIDGEWOOD AVENUE, PARAMUS
Compare PLYX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLYX
Polaryx Therapeutics Inc
|
2.31 | 116.64M | 0 | -6.48M | -5.30M | -0.137 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polaryx Therapeutics Inc Stock (PLYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Initiated | Maxim Group | Buy |
Polaryx Therapeutics Inc Stock (PLYX) Latest News
Polaryx Therapeutics Inc (PLYX) Stock Price, Quote, News & History - Benzinga
PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech - Stocktwits
Polaryx Therapeutics (PLYX) Faces Pressure After 6.7% Drop: Key Support Levels in FocusHead and Shoulders - newsline.com
Polaryx Therapeutics, Inc. Common Stock (PLYX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Polaryx Therapeutics (PLYX) Stock Chart and Price History 2026 - MarketBeat
Polaryx Therapeutics CEO’s Mstone buys $360,003 in PLYX stock By Investing.com - Investing.com Australia
Polaryx Therapeutics (PLYX) Insider Trading Activity 2026 - MarketBeat
Polaryx Therapeutics CEO’s Mstone buys $360,003 in PLYX stock - Investing.com
MStone affiliate of Polaryx Therapeutics (PLYX) buys 88K common shares - Stock Titan
PLYXPolaryx Therapeutics Inc. stock news, filings & ratings - Quantisnow
Polaryx (PLYX) secures $10M PIPE to fund SOTERIA trial and extend runway to Q2 2027 - Stock Titan
Why Polaryx Therapeutics Stock Is Surging On Thursday? - Benzinga
Polaryx Therapeutics closes $10 million PIPE financing By Investing.com - Investing.com Nigeria
Polaryx Therapeutics closes $10 million PIPE financing - Investing.com
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial - marketscreener.com
Polaryx Therapeutics, Inc. announced that it has received $10.010784 million in funding - marketscreener.com
Polaryx Therapeutics (PLYX) Slips 2.71% as Stock Tests Key Support Near $2.38Growth ETF - The Legal Advocate
thanks & goodnight ! - Moomoo
Polaryx Therapeutics (PLYX) Slips 8.63% as Biotech Volatility Resurfaces – Key Support Levels in FocusGap Fill Strategy - newsline.com
PLYX Technical Analysis | Trend, Signals & Chart Patterns | POLARYX THERAPEUTICS INC (NASDAQ:PLYX) - ChartMill
Polaryx Therapeutics, Inc. Q1 2026 Financial Results and Pipeline Update: Progress in Rare Pediatric Lysosomal Storage Disorder Therapies - Minichart
Polaryx Therapeutics (NASDAQ: PLYX) narrows loss but flags going concern risk - Stock Titan
Polaryx Therapeutics 1Q 2026: Net income $(2.54M), EPS $(0.05) — 10-Q Summary - TradingView
Polaryx Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Polaryx Therapeutics Awarded Double Honors at the 2026 GHP Healthcare & Pharmaceutical Awards - Quiver Quantitative
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards - The Manila Times
Biotech for rare pediatric lysosomal diseases wins 2 GHP awards - Stock Titan
PLYX Stock Price, Quote & Chart | POLARYX THERAPEUTICS INC (NASDAQ:PLYX) - ChartMill
Number of shareholders of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
Polaryx Therapeutics (NASDAQ:PLYX) Shares Down 16.3%What's Next? - MarketBeat
Polaryx Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Technical Analysis of Polaryx Therapeutics, Inc. (NASDAQ:PLYX) - TradingView
PLYX Polaryx Therapeutics highlights rare disease pipeline progress in its newly released quarterly earnings report.Verified Stock Signals - Newser
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference - The Manila Times
Polaryx heads to Tay-Sachs family meeting with Phase 2 program - Stock Titan
FDA grants fast track status to Polaryx’s PLX-200 for three rare diseases - Investing.com Nigeria
Polaryx receives U.S. FDA Fast Track Designation for PLX-200 - TipRanks
Polaryx Therapeutics Gets FDA Fast Track Designations for Its Lead Drug Candidate - marketscreener.com
Polaryx Therapeutics receives U.S. FDA fast track designations for all four indications to be evaluated in the Soteria Basket Trial - marketscreener.com
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial - The Manila Times
FDA fast-tracks Polaryx drug for 4 rare childhood disorders - Stock Titan
Does Polaryx Therapeutics (PLYX) Stock Pay Dividends? (Underperforming) 2026-04-20Real Trader Network - Cổng thông tin điện tử Tỉnh Sơn La
PLYX Should I Buy - Intellectia AI
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care - The Manila Times
A rare-disease biotech, Polaryx, just won a pediatric care award - Stock Titan
Number of employees of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
What makes Polaryx Therapeutics (PLYX) Stock attractive or not | Price at $5.63, Down 2.26%Earnings Breakout Stocks - newsline.com
PLYX Stock Price and Chart — NASDAQ:PLYX - TradingView
Polaryx Therapeutics, Inc.Common Stock (NQ: PLYX - The Chronicle-Journal
Polaryx Therapeutics, Inc. News — NASDAQ:PLYX - TradingView
Polaryx Therapeutics Inc Stock (PLYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Polaryx Therapeutics Inc Stock (PLYX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Landis G. Michael | Chief Financial Officer |
Feb 18 '26 |
Buy |
2.79 |
2,867 |
7,991 |
228,225 |
2.60%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):